Otros idiomas Corbus Pharmaceuticals Holdings, Inc.

Acciones

CRBP

US21833P3010

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
37,35 ^USD	+0,84 %		-1,03 %	+518,38 %

02/04	Corbus Pharmaceuticals Holdings, Inc. anuncia la dosificación del primer paciente en EE.UU. del ensayo clínico de fase 1 de su ADC de nueva generación dirigido a la Nectina-4	CI
13/03	Corbus Pharmaceuticals presenta una declaración de registro mixta	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum	01/05
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting	24/04
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02/04
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02/04
Corbus Pharmaceuticals Files Mixed Shelf	13/03
Health Care Climbs on Risk Appetite -- Health Care Roundup	12/03
Corbus Pharmaceuticals: Q4 Earnings Snapshot	12/03
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	12/03
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
North American Morning Briefing : Inflation Data -2-	12/03
North American Morning Briefing : Powell Still in -2-	07/03
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit	06/03
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	29/02
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer	28/02
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	06/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Corbus Pharmaceuticals Holdings, Inc.

Acciones

CRBP

US21833P3010

Otros idiomas

Filtros